Orthofix Medical Inc. SEC 10-Q Report
Orthofix Medical Inc. has released its Form 10-Q report for Q3 2025, showing financial improvements with net sales of $205.6 million, a 4.6% increase from Q3 2024. Gross profit rose to $148.5 million, reflecting a 10% increase. The operating loss improved to $(17.0) million, and net loss decreased to $(22.8) million. Key growth drivers included Bone Growth Therapies and Spinal Implants, with significant contributions from the U.S. market. The company expects continued growth in core product lines and plans to focus on profitable opportunities after discontinuing the M6 product lines.
Orthofix Medical Inc., a global medical device company focused on musculoskeletal products and therapies, has released its Form 10-Q report for the third quarter of 2025. The report highlights significant financial and operational improvements, driven by growth in key product segments and strategic business decisions.
Financial Highlights
Net Sales: $205.6 million, representing an increase of 4.6% compared to the third quarter of 2024, driven by growth in Bone Growth Therapies and Spinal Implants.
Gross Profit: $148.5 million, an increase of 10.0% from the prior year period, with a gross margin of 72.2%, reflecting improved efficiency and reduced costs from discontinuing the M6 product lines.
Operating Loss: $(17.0) million, a slight improvement from the $(18.9) million loss in the third quarter of 2024, due to cost management and increased sales.
Net Loss: $(22.8) million, compared to $(27.4) million in the third quarter of 2024, reflecting reduced interest expenses and improved foreign exchange impacts.
Net Loss Per Common Share - Basic and Diluted: $(0.57), compared to $(0.71) in the third quarter of 2024, indicating a reduction in loss per share due to improved financial performance.
Business Highlights
Revenue Segments - Global Spine: The Global Spine segment saw a 3.6% increase in net sales to $172.1 million for the three months ended September 30, 2025. This growth was driven by a 5.7% increase in Bone Growth Therapies and a 5.6% increase in Spinal Implants, Biologics, and Enabling Technologies, excluding the M6 product lines.
Revenue Segments - Global Orthopedics: Global Orthopedics reported a 10.1% increase in net sales to $33.6 million for the three months ended September 30, 2025, with U.S. sales growing by 18.5% due to recent product launches and commercial execution.
Geographical Performance - U.S.: The U.S. market contributed significantly to the company's performance, with Global Spine and Global Orthopedics segments showing strong growth due to increased sales volumes and successful product launches.
Geographical Performance - International: International sales for Global Spine increased by 1.0% on a constant currency basis, driven by new product launches and offset by prior year large orders from NGOs.
Sales Units - Bone Growth Therapies: Bone Growth Therapies experienced a 5.7% increase in net sales, attributed to higher order volumes and continued share growth of the AccelStim product.
Sales Units - Spinal Implants: Spinal Implants saw growth in cervical, interbody, and thoracolumbar franchises, contributing to the overall increase in the Global Spine segment.
New Product Launches: The company continued to benefit from recent product launches, particularly in the Global Orthopedics segment, which contributed to the growth in U.S. sales.
Future Outlook: The company anticipates continued growth in its core product lines and plans to focus resources on more profitable growth opportunities, following the discontinuation of the M6 product lines.
SEC Filing: Orthofix Medical Inc. [ OFIX ] - 10-Q - Nov. 04, 2025
